Related Experiment Video

Updated: Oct 6, 2025

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K

RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53

Lei Duan1,2, Ricardo E Perez3, Sarah Calhoun4,5

  • 1Department of Anatomy and Cell Biology, Rush University Medical Center, 600 S. Paulina Ave, AcFac 507, Chicago, IL, 60612, USA. Lei_Duan@Rush.edu.

Scientific Reports
|January 21, 2022
PubMed

Insights

Wild-type p53 (protein 53) suppresses tumors by repressing aurora kinase A/B (AURKA/B) genes. This repression improves outcomes and therapy response in non-small cell lung cancer patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cancer Genetics

Background:

  • Wild-type p53 is a crucial tumor suppressor that regulates cell cycle and apoptosis.
  • p53-mediated transcription repression involves RB-family proteins and DREAM complexes.
  • The aurora kinase A/B (AURKA/B) pathway is implicated in cell proliferation and cancer.

Purpose of the Study:

  • To investigate the role of p53-RBL2-DREAM complex in regulating AURKA/B pathway genes.
  • To determine the association between RBL2 expression, AURKA/B pathway activity, and patient outcomes in non-small cell lung cancer (NSCLC).
  • To explore the therapeutic implications of targeting the p53-DREAM-AURKA/B axis in NSCLC.

Main Methods:

  • Analysis of gene expression data from NSCLC patients.
  • Gene knockdown experiments using siRNA targeting p53, RBL2, and LIN37.
  • Pharmacologic inhibition of AURKA/B.
  • Assessment of sensitivity to paclitaxel and radiation therapy in NSCLC cells.

Main Results:

  • Heightened RBL2 expression and reduced AURKA/B pathway gene expression correlated with better outcomes in wild-type p53 NSCLC.
  • Knockdown of p53, RBL2, or LIN37 led to increased AURKA/B gene expression and reduced sensitivity to paclitaxel and radiation.
  • Inhibition or knockdown of AURKA/B components enhanced sensitivity to paclitaxel and radiation therapy.

Conclusions:

  • p53-RBL2-DREAM-mediated repression of the AURKA/B pathway is a key tumor suppressor mechanism.
  • This pathway contributes to improved therapeutic responses and outcomes in p53 wild-type NSCLC.
  • Targeting the AURKA/B pathway represents a potential therapeutic strategy for NSCLC.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K